Home › NCT06654219
Protective Benefits of a Clear Liquid Diet on Residual Gastric Content in Patients Taking Glucagon Like Peptide-1 Receptor (GLP-1 RA) Agonist Prior to Anesthesia
Protective Benefits of a Clear Liquid Diet on Residual Gastric Content in Patients Taking Glucagon Like Peptide-1 Receptor Agonist Prior to Anesthesia
Who can join
Ages 18 and older · All sexes
Full eligibility criteria
Inclusion Criteria: * Patients taking Glucagon Like Peptide-1 Receptor (GLP-1 RA) agonists * Undergoing upper endoscopy only - no colonoscopy due to prep Exclusion Criteria: * Previous gastric resection or bypass * Gastric band in situ * Previous fundoplication * Large hiatal hernia * Pregnant patients * Recent trauma * Inability to turn to the right lateral decubitus position. * Patients on erythromycin, metoclopramide, domperidone, opioids. * Gastroparesis previous
About the study
The purpose of this study is to determine if prolonged fasting from solids and transitioning to a CLD for 24 hours is protective to decrease RGC in patients on GLP-1 RAs presenting for upper endoscopy, to determine if prolonged fasting is associated with increased thirst, hunger and anxiety, To determine if signs and symptoms of nausea, vomiting, retching, abdominal bloating, and abdominal pain are present on the day of surgery, to see if there is any variability between preoperative gastric ultrasound assessment and volume of gastric contents visualized on upper endoscopy, to determine time of gastric emptying by serial Gastric ultrasonography (GUS) scans every 2 hours in subjects who presented with an initial at-risk scan, to determine the choice of anesthesia used based on preoperative GUS results, to determine if there were any adverse events recorded in this study group, to determine if duration of GLP-1 RA therapy has an association with residual gastric content (RGC). and to determine if dosing of GLP-1 RA has an association with RGC.
What is being tested
- GLP-1 RA users with prolonged fasting instructions (other)
- GLP-1 RA users with standard NPO instructions (other)
Sponsor: The University of Texas Health Science Center, Houston · Participants: 136 · Started: Oct 30, 2025
Contact the study team
- Sudipta Sen, MD, FASA · Phone: (713) 500-6202
- Paul Potnuru · Phone: (713) 500-6271
Official record on ClinicalTrials.gov — NCT06654219
Locations in the U.S.
| Texas | The University of Texas Health Science Center at Houston, Houston |
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.